Abstract
Seven patients with anti-aquaporin-4 antibody–positive neuromyelitis optica (NMO) or NMO spectrum disorders were recruited on the basis of their limited responsiveness to their current treatment. This study showed that monthly IV injections of tocilizumab, an anti–interleukin-6 receptor antibody, reduced relapses, neurogenic pain, and fatigue in patients with NMO. See p. 1302 From editorialists Rose-John & Gold: “Given the expression pattern of IL-6, targeting the bioactivity of this cytokine is a rational therapeutic approach for the treatment of autoimmune diseases.” See p. 1294 Combining advanced structural and functional imaging …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
